Table 2.

Primary and motor secondary outcomes

	Ziclague®		Placebo		95% CI	SE	p-values
	Pre	Post	Pre	Post
Outcomes	N = 52	N = 52	N = 52	N = 52
Primary outcome •
Self-selected gait velocity (m/s)	0.85 (±0.31)	0.86 (±0.34)	0.81 (±0.31)	0.86 (±0.31)	[-0.07, 0.01]	0.02	0.17
Secondary outcomes •
Maximal gait velocity (m/s)	1.17 (±0.44)	1.17 (±0.45)	1.11 (±0.46)	1.17 (±0.46)	[-0.09, -0.01]	0.02	0.04
Endurance walking by 6MWT (m)	250.0 (±94.6)	249.3 (±103.4)	244.6 (±96.3)	249.6 (±95.1)	[-14.70, 4.90]	5.0	0.32
Spasticity (MAS)
Hip adductors muscles	1.69 (±0.79)	1.54 (±0.68)	1.74 (±0.85)	1.61 (±0.72)	[-0.58, 1.02]	0.41	0.59
Triceps surae muscles	1.88 (±0.77)	1.86 (±0.79)	1.85 (±0.87)	1.73 (±0.82)	[-0.56, 1.04]	0.41	0.56
Muscle strength (MRC)
Hip adductors muscles	4.60 (±0.66)	4.58 (±0.79)	4.50 (±0.82)	4.58 (±0.70)	NA	1.20	0.41
Triceps surae muscles	4.48 (±0.93)	4.54 (±0.79)	4.50 (±0.82)	4.56 (±0.82)	[-0.51, 2.19]	0.69	0.23

Primary and motor secondary outcomes: mean values (±standard deviation), 95% CI, standard error and p-values, obtained by GEE models. Considered on patients who completed at least two visits of the clinical trial (N = 52). 6MWT, 6-minute walking test; CI, confidence interval; MAS, modified Ashworth scale; MRC, Medical Research Council scale; NA, not applicable; SE, standard error